Literature DB >> 28356445

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Brian W McCrindle, Anne H Rowley, Jane W Newburger, Jane C Burns, Anne F Bolger, Michael Gewitz, Annette L Baker, Mary Anne Jackson, Masato Takahashi, Pinak B Shah, Tohru Kobayashi, Mei-Hwan Wu, Tsutomu T Saji, Elfriede Pahl.   

Abstract

BACKGROUND: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries. METHODS AND
RESULTS: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up.
CONCLUSIONS: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  AHA Scientific Statements; Kawasaki syndrome; aneurysm; arteritis; coronary vessels; immunoglobulins, intravenous; thrombosis; vasculitis

Mesh:

Year:  2017        PMID: 28356445     DOI: 10.1161/CIR.0000000000000484

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  748 in total

1.  Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis.

Authors:  Yuan Zhang; Yanfei Wang; Li Zhang; Luoxing Xia; Minhui Zheng; Zhi Zeng; Yingying Liu; Timur Yarovinsky; Allison C Ostriker; Xuejiao Fan; Kai Weng; Meiling Su; Ping Huang; Kathleen A Martin; John Hwa; Wai Ho Tang
Journal:  Circ Res       Date:  2020-06-29       Impact factor: 17.367

2.  Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease.

Authors:  André Jakob; Eva Schachinger; Simon Klau; Anja Lehner; Sarah Ulrich; Brigitte Stiller; Barbara Zieger
Journal:  Eur J Pediatr       Date:  2019-11-23       Impact factor: 3.183

3.  Familial Kawasaki disease and acute glomerulonephritis: case report and review of literature.

Authors:  Sarah A Salam Salih; Abdelbasit M A Elbashier; Nazik Abd Alaziz Alameen
Journal:  Sudan J Paediatr       Date:  2020

4.  The factors affecting the disease course in Kawasaki disease.

Authors:  Elif Arslanoglu Aydin; Ilker Ertugrul; Yelda Bilginer; Ezgi Deniz Batu; Hafize Emine Sonmez; Selcan Demir; Zehra Serap Arici; Erdal Sag; Dursun Alehan; Seza Ozen
Journal:  Rheumatol Int       Date:  2019-05-28       Impact factor: 2.631

5.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

6.  Oxidised Low-Density Lipoprotein and Its Receptor-Mediated Endothelial Dysfunction Are Associated with Coronary Artery Lesions in Kawasaki Disease.

Authors:  Yue-E He; Hui-Xian Qiu; Rong-Zhou Wu; Xing Rong; Hai-Tang Xu; Ru-Lian Xiang; Mao-Ping Chu
Journal:  J Cardiovasc Transl Res       Date:  2019-08-19       Impact factor: 4.132

7.  Arterial immune protein expression demonstrates the complexity of immune responses in Kawasaki disease arteritis.

Authors:  S A Cameron; S M White; D Arrollo; S T Shulman; A H Rowley
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

8.  Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?

Authors:  Rae Sm Yeung; Polly J Ferguson
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

9.  Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease.

Authors:  Marianna Fabi; Laura Andreozzi; Ilaria Frabboni; Ada Dormi; Elena Corinaldesi; Francesca Lami; Cristina Cicero; Bertrand Tchana; Rosa Francavilla; Monica Sprocati; Barbara Bigucci; Claudia Balsamo; Paola Sogno Valin; Giorgia Di Fazzio; Lorenzo Iughetti; Enrico Valletta; Federico Marchetti; Andrea Donti; Marcello Lanari
Journal:  Clin Rheumatol       Date:  2020-09-16       Impact factor: 2.980

10.  Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease.

Authors:  Sarah D de Ferranti; Kimberlee Gauvreau; Kevin G Friedman; Alexander Tang; Annette L Baker; David R Fulton; Adriana H Tremoulet; Jane C Burns; Jane W Newburger
Journal:  JAMA Pediatr       Date:  2018-12-03       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.